Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results
Globe Newswire (Fri, 14-Nov 7:30 AM ET)
Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value
Globe Newswire (Thu, 30-Oct 9:00 AM ET)
Market Chameleon (Fri, 17-Oct 4:28 AM ET)
Globe Newswire (Fri, 17-Oct 8:00 AM ET)
Globe Newswire (Tue, 23-Sep 7:30 AM ET)
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
Sensei Biotherapeutics trades on the NASDAQ stock market under the symbol SNSE.
As of December 19, 2025, SNSE stock price declined to $8.86 with 15,858 million shares trading.
SNSE has a beta of 1.92, meaning it tends to be more sensitive to market movements. SNSE has a correlation of 0.11 to the broad based SPY ETF.
SNSE has a market cap of $11.17 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, SNSE traded as high as $38.80 and as low as $5.00.
The top ETF exchange traded funds that SNSE belongs to (by Net Assets): VXF, DFSU.
SNSE has underperformed the market in the last year with a price return of +3.0% while the SPY ETF gained +18.1%. SNSE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -1.6% and -8.8%, respectively, while the SPY returned +2.8% and -0.5%, respectively.
SNSE support price is $8.20 and resistance is $10.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNSE shares will trade within this expected range on the day.